Pantoprazole BEXIMCO 20 mg Gastro-Resistant Tablet

Country: Malasja

Lingwa: Ingliż

Sors: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Ingredjent attiv:

PANTOPRAZOLE SODIUM SESQUIHYDRATE

Disponibbli minn:

Vitamode Sdn.bhd

INN (Isem Internazzjonali):

PANTOPRAZOLE SODIUM SESQUIHYDRATE

Unitajiet fil-pakkett:

3 x 10tablet Tablets

Manifatturat minn:

BEXIMCO PHARMACEUTICAL LTD

Fuljett ta 'informazzjoni

_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP) _
PANTOPRAZOLE BEXIMCO 20MG/40MG GASTRO-
RESISTANT TABLET
Pantoprazole Sodium USP equivalent to Pantoprazole 20mg/40mg
1
WHAT IS IN THIS LEAFLET
1.
What Pantoprazole Tablet is used
for
2.
How Pantoprazole Tablet works
3.
Before you use Pantoprazole Tablet
4.
How to use Pantoprazole Tablet
5.
While you are using it
6.
Side effects
7.
Storage and Disposal of
Pantoprazole Tablet
8.
Product Description
9.
Manufacturer and Product
Registration Holder
10.
Date of revision
Please read this leaflet carefully before
you start using Pantoprazole Tablet. It
will advise you how it should be taken
properly and when to tell your doctor
about
health-related
conditions.
If
you
have any questions or need more advice,
ask your doctor, professional healthcare
provider or pharmacist.
WHAT PANTOPRAZOLE TABLET
IS USED FOR
Pantoprazole
BEXIMCO
Gastro-
Resistant Tablet is a selective “proton
pump
inhibitors”,
which
is
used
for
treating
acid-related
disease
of
the
stomach and intestine.
PANTOPRAZOLE
BEXIMCO
20
MG
GASTRO-RESISTANT TABLET
Treatment
of
mild
reflux
disease
and
associated symptoms (eg, heartburn, acid
regurgitation, pain on swallowing); long-
term
management
and
prevention
of
relapse in reflux esophagitis; prevention
of stomach and intestinal ulcers induced
by nonsteroidal anti-inflammatory drugs
(NSAIDs), in patients at risk with a need
for a continuous NSAID treatment.
PANTOPRAZOLE
BEXIMCO
40
MG
GASTRO-RESISTANT TABLET
In
combination
with
2
appropriate
antibiotics
for
the
eradication
of Helicobacter
pylori in
patients
with
stomach ulcers to reduce recurrence of
intestine and stomach ulcers caused by
the
microorganism;
intestine
and
stomach ulcers.
Also for treating:
REFLUX OESOPHAGITIS:
An inflammation
of
your
oesophagus
(the
tube
which
connects your throat to your stomach)
accompanied
by
the
regurgitation
of
stomach acid.
ZOLLINGER-ELLISON
SYNDROME:
A
rare
disorder
caused
by
a
tumor
called
a
gastrinoma, most often occurring in the
pancreas.
The
tumor
secretes
the
hormone

Karatteristiċi tal-prodott

Pantoprazole BEXIMCO 20 & 40 mg Gastro-Resistant Tablet
PRODUCT DESCRIPTION
Pantoprazole gastro-resistant tablets are yellow colored, oval,
biconvex,
enteric coated tablets plain on both sides.
PANTOPRAZOLE BEXIMCO 20 MG GASTRO-RESISTANT TABLET:
Length: 9.0mm ± 2mm
Width: 4.8mm ± 2mm
PANTOPRAZOLE BEXIMCO 40 MG GASTRO-RESISTANT TABLET:
Length: 11.9mm ± 2mm
Width: 6.0mm ± 2mm
PHARMACODYNAMICS
Pantoprazole is a substituted benzimidazole which inhibits the
secretion of
hydrochloric acid in the stomach by specific blockade of the proton
pumps
of the parietal cells.
Pantoprazole is converted to its active form in the acidic environment
in the
parietal cells where it inhibits the H+, K+-ATPase enzyme, i.e. the
final
stage in the production of hydrochloric acid in the stomach. The
inhibition is
dose-dependent and affects both basal and stimulated acid secretion.
In
most patients, freedom from symptoms is achieved within 2 weeks. As
with
other proton pump inhibitors and H2 receptor inhibitors, treatment
with
Pantoprazole reduces acidity in the stomach and thereby increases
gastrin
in proportion to the reduction in acidity. The increase in gastrin is
reversible.
Since Pantoprazole binds to the enzyme distal to the cell receptor
level, it
can inhibit hydrochloric acid secretion independently of stimulation
by other
substances (acetylcholine, histamine, gastrin). The effect is the same
whether the product is given orally or intravenously.
The fasting gastrin values increase under Pantoprazole. On short-term
use, in most cases they do not exceed the upper limit of normal.
During
long-term treatment, gastrin levels double in most cases. An excessive
increase, however, occurs only in isolated cases. As a result, a mild
to
moderate increase in the number of specific endocrine (ECL) cells in
the
stomach is observed in a minority of cases during long-term treatment
(simple to adenomatoid hyperplasia). However, so far, the formation of
carcinoid precursors (atypical hyperplasia) or gastric carcinoids have
not
been observed in h